Preclinical development of an EP2 antagonist for post-seizure cognitive deficits.
Varvel NH, Amaradhi R, Espinosa-Garcia C, Duddy S, Franklin R, Banik A, Alemán-Ruiz C, Blackmer-Raynolds L, Wang W, Honore T, Ganesh T, Dingledine R.
Varvel NH, et al. Among authors: dingledine r.
Neuropharmacology. 2023 Feb 15;224:109356. doi: 10.1016/j.neuropharm.2022.109356. Epub 2022 Nov 30.
Neuropharmacology. 2023.
PMID: 36460083
Free PMC article.